+1 Recommend
0 collections
      • Record: found
      • Abstract: found
      • Article: not found

      High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to initial breast-conserving surgery. This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant chemotherapy. Between 1989 and 1999, 750 patients with clinical stage II/IIIA ductal (672) or lobular (78) invasive breast carcinomas were treated at the Institut Curie with primary anthracycline-based polychemotherapy followed by either breast conservation (surgery and/or radiotherapy) or mastectomy. Median follow-up was 10 years. Clinical response to primary chemotherapy was significantly worse for lobular than for ductal carcinomas (47 vs 60%; P=0.04), but only histological grade remained predictive in multivariate analysis. Breast conservation was high for both ductal and lobular carcinomas (65 and 54%; P=0.07), due, in part, to the use of radiotherapy, either exclusive or preoperative, for respectively 26 and 40% of patients. The lobular type had no adverse effect, neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

          Molecular classification of breast cancer has been proposed based on gene expression profiles of human tumors. Luminal, basal-like, normal-like, and erbB2+ subgroups were identified and were shown to have different prognoses. The goal of this research was to determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy. Fine needle aspirations of 82 breast cancers were obtained before starting preoperative paclitaxel followed by 5-fluorouracil, doxorubicin, and cyclophosphamide chemotherapy. Gene expression profiling was done with Affymetrix U133A microarrays and the previously reported "breast intrinsic" gene set was used for hierarchical clustering and multidimensional scaling to assign molecular class. The basal-like and erbB2+ subgroups were associated with the highest rates of pathologic complete response (CR), 45% [95% confidence interval (95% CI), 24-68] and 45% (95% CI, 23-68), respectively, whereas the luminal tumors had a pathologic CR rate of 6% (95% CI, 1-21). No pathologic CR was observed among the normal-like cancers (95% CI, 0-31). Molecular class was not independent of conventional cliniocopathologic predictors of response such as estrogen receptor status and nuclear grade. None of the 61 genes associated with pathologic CR in the basal-like group were associated with pathologic CR in the erbB2+ group, suggesting that the molecular mechanisms of chemotherapy sensitivity may vary between these two estrogen receptor-negative subtypes. The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers.
            • Record: found
            • Abstract: found
            • Article: not found

            Histological Grading and Prognosis in Breast Cancer

            Images Figs. 19-24 Figs. 7-12 Figs. 1-6 Figs. 13-18 Figs. 33-36 Figs. 25-29
              • Record: found
              • Abstract: found
              • Article: not found

              Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

              We sought to identify gene expression markers that predict the likelihood of chemotherapy response. We also tested whether chemotherapy response is correlated with the 21-gene Recurrence Score assay that quantifies recurrence risk. Patients with locally advanced breast cancer received neoadjuvant paclitaxel and doxorubicin. RNA was extracted from the pretreatment formalin-fixed paraffin-embedded core biopsies. The expression of 384 genes was quantified using reverse transcriptase polymerase chain reaction and correlated with pathologic complete response (pCR). The performance of genes predicting for pCR was tested in patients from an independent neoadjuvant study where gene expression was obtained using DNA microarrays. Of 89 assessable patients (mean age, 49.9 years; mean tumor size, 6.4 cm), 11 (12%) had a pCR. Eighty-six genes correlated with pCR (unadjusted P < .05); pCR was more likely with higher expression of proliferation-related genes and immune-related genes, and with lower expression of estrogen receptor (ER) -related genes. In 82 independent patients treated with neoadjuvant paclitaxel and doxorubicin, DNA microarray data were available for 79 of the 86 genes. In univariate analysis, 24 genes correlated with pCR with P < .05 (false discovery, four genes) and 32 genes showed correlation with P < .1 (false discovery, eight genes). The Recurrence Score was positively associated with the likelihood of pCR (P = .005), suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit. Quantitative expression of ER-related genes, proliferation genes, and immune-related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel.

                Author and article information

                Br J Cancer
                British Journal of Cancer
                Nature Publishing Group
                05 February 2008
                19 February 2008
                26 February 2008
                : 98
                : 4
                : 734-741
                [1 ]Department of Radiation Oncology, Institut Curie, Paris cedex 05 Paris 75248, France
                [2 ]Department of Biostatistics, Institut Curie, Paris cedex 05 Paris 75248, France
                [3 ]Department of Medical Oncology, Institut Curie, Paris cedex 05 Paris 75248, France
                [4 ]Department of Pathology, Institut Curie, Paris cedex 05 Paris 75248, France
                [5 ]Department of Surgery, Institut Curie, Paris cedex 05 Paris 75248, France
                Author notes
                [* ]Author for correspondence: marc.bollet@ 123456curie.net
                Copyright 2008, Cancer Research UK
                : 08 August 2007
                : 10 December 2007
                : 07 January 2008
                Clinical Studies

                Oncology & Radiotherapy
                chemotherapy,neoadjuvant,multimodality,breast cancer,radiotherapy
                Oncology & Radiotherapy
                chemotherapy, neoadjuvant, multimodality, breast cancer, radiotherapy


                Comment on this article